Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension

Not Applicable

• Conditions: Pulmonary Arterial Hypertension
• Interventions: Diagnostic Test: Hyperventilation test

• Registration Number: NCT03810443
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension. The hyperventilation syndrome is a frequent cause of dyspnea in general population and in respiratory diseases like asthma but has never been studied in pulmonary hypertension. The goal of this study is to measure the prevalence of pulmonary hypertension in a population of patients with controlled pulmonary arterial hypertension (PAH).

Detailed Description

Hyperventilation syndrome has been described as a cause of dyspnea in the general population and in several chronic respiratory diseases such as asthma with 20 to 40% of asthmatics affected. However, Hyperventilation syndrome has never been sought in a population with PAH. Hyperventilation syndrome, although complex pathophysiology, may be simply corrected by a management of respiratory physiotherapy based on the control of respiration.

Study Timeline

• Status Verified: 2018-12
• Study First Submitted: 2018-12-20
• Study Start: 2019-01-14
• Study First Submitted QC: 2019-01-17
• Last Update Submitted: 2019-01-17
• Study First Posted: 2019-01-18
• Last Update Posted: 2019-01-18
• Primary Completion: 2021-07-14
• Study Completion: 2021-07-14

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Non smoker or tobacco stopped for minimum 2 years ans maximum 10 year-pack. - Idiopathic, heritable, related to drug or toxics, associated with controlled pulmonary hypertension. Diagnosis and treatment of pulmonary hypertension for more than 4 months.
• Optimal control of pulmonary hypertension (no right heart failure symptom and NTproBNP < 300ng/L or Brain Natriuretic Peptide(BNP) < 50 ng/L and optimal hemodynamic results measured by a right heart catheterization in the last year: right atrial pressure < 8 mmHg, cardiac index > 2,5 L/min/m2, veinous saturation in oxygen > 65%)
• Informed and written consent
• Non-affiliation to a social security

Exclusion Criteria

• Existence of another form of pulmonary hypertension
• Existence of vocal cord dysfunction
• Pregnancy
• Obesity> stage 2 (BMI 35 kg / m2)
• Age ≥ 75 years

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
pulmonary arterial hypertension	Hyperventilation test	The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.

Primary Outcome Measures

Name	Time	Method
Prevalence of the hyperventilation syndrome	18 months	Prevalence of the hyperventilation syndrome in a population with pulmonary arterial hypertension

Secondary Outcome Measures

Name	Time	Method
anxiety-depression questionary score	18 months	results of anxiety-depression questionary
dyspnea score	18 months	results of dyspnea questionary
quality of life score	18 months	results of quality of life questionary

Trial Locations

Locations (1)

Hôpital Bicêtre - Pneumology department; 🇫🇷 Le Kremlin-Bicêtre, France